| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| Other Sizes |
| Targets |
Not applicable. This compound is a reagent for oligonucleotide synthesis, not a drug. It does not have a biological target itself; it is a building block for creating nucleic acid-based therapeutics (e.g., antisense oligonucleotides, siRNA). Its modifications are designed to improve the pharmacological properties of the resulting oligonucleotides.
|
|---|---|
| ln Vitro |
No significant direct in vitro activity reported. As a monomer, it is not biologically active. Its activity is realized only after being incorporated into a full-length oligonucleotide sequence, where the cEt modification improves nuclease resistance and hybridization affinity to target RNA. The purity of the amidite is typically ≥98% for coupling reactions.
|
| ln Vivo |
No specific in vivo data reported. As a synthesis reagent, the compound's value is in producing oligonucleotide drugs. Once incorporated into an oligonucleotide, the modifications enhance in vivo stability (nuclease resistance) and pharmacokinetic properties, leading to improved efficacy in animal models. The cEt modification is known to improve the potency of antisense oligonucleotides.
|
| Enzyme Assay |
Not applicable. This is a chemical reagent used in solid-phase oligonucleotide synthesis. A typical coupling protocol involves dissolving the phosphoramidite (50-100 mM) in anhydrous acetonitrile. Using a DNA synthesizer, the amidite is activated with 5-benzylthio-1H-tetrazole (0.25 M) and coupled to the free 5'-OH of an immobilized, detritylated nucleoside. The coupling reaction is carried out over 2-5 minutes, achieving coupling efficiencies >98%.
|
| Cell Assay |
Not applicable. The compound is used for chemical synthesis, not cell-based assays. However, the fully synthesized and purified oligonucleotides incorporating this amidite can be tested in cell culture. Cells are treated with the oligonucleotides (e.g., lipofectamine-mediated transfection at 10-200 nM) for 24-96 hours. Knockdown of a target gene is assessed by qPCR or Western blot, and off-target effects are evaluated by RNA sequencing.
|
| Animal Protocol |
No specific in vivo animal study protocols are documented for the amidite itself. However, for the antisense oligonucleotides derived from it, a typical protocol would involve intravenous (i.v.) or subcutaneous (s.c.) administration in rodents at doses of 1-50 mg/kg, administered daily or twice weekly. Tissues (liver, kidney) are collected to quantify target mRNA reduction by qPCR and to measure oligonucleotide concentration by LC-MS/MS.
|
| ADME/Pharmacokinetics |
Not applicable for the amidite. For the resulting oligonucleotides, the cEt (constrained ethyl) modification is known to confer high resistance to endo- and exonucleases, resulting in a long plasma half-life (e.g., 2-8 hours in rodents) and high tissue exposure. Metabolism is primarily through nuclease-mediated chain shortening, not Cyp450 enzymes.
|
| Toxicity/Toxicokinetics |
No toxicity data reported. As a chemical reagent, it is an irritant. For the resulting oligonucleotides, the cEt modification generally reduces the pro-inflammatory side effects (e.g., cytokine release) associated with unmodified phosphorothioate oligonucleotides, but can cause hepatotoxicity at high doses. Long-term toxicology studies are compound-specific.
|
| References | |
| Additional Infomation |
This is a key building block for the production of next-generation antisense oligonucleotides (ASOs). The constrained ethyl (cEt) bicyclic ring structure locks the sugar in a favorable conformation, greatly increasing binding affinity (Tm) to complementary RNA and providing superior nuclease resistance compared to first-generation modifications. Its IUPAC name is N-[1-[(1S,3R,4R,6S,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-[di(propan-2-yl)amino]phosphanyl]oxy-6-methyl-2,5-dioxabicyclo[2.2.1]heptan-3-yl]-5-methyl-2-oxopyrimidin-4-yl]benzamide; molecular formula: C49H56N5O9P; molecular weight: 889.97.
|
| Molecular Formula |
C49H56N5O9P
|
|---|---|
| Molecular Weight |
889.97
|
| Exact Mass |
889.382
|
| CAS # |
1197033-17-2
|
| PubChem CID |
45139840
|
| Appearance |
White to off-white solid powder
|
| LogP |
8.38
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
19
|
| Heavy Atom Count |
64
|
| Complexity |
1640
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C[C@H]1[C@]2([C@H]([C@@H](O1)[C@@H](O2)N3C=C(C(=NC3=O)NC(=O)C4=CC=CC=C4)C)OP(N(C(C)C)C(C)C)OCCC#N)COC(C5=CC=CC=C5)(C6=CC=C(C=C6)OC)C7=CC=C(C=C7)OC
|
| InChi Key |
BDTXILPCBUAYPJ-USFFSJIASA-N
|
| InChi Code |
InChI=1S/C49H56N5O9P/c1-32(2)54(33(3)4)64(60-29-15-28-50)63-43-42-46(53-30-34(5)44(52-47(53)56)51-45(55)36-16-11-9-12-17-36)62-48(43,35(6)61-42)31-59-49(37-18-13-10-14-19-37,38-20-24-40(57-7)25-21-38)39-22-26-41(58-8)27-23-39/h9-14,16-27,30,32-33,35,42-43,46H,15,29,31H2,1-8H3,(H,51,52,55,56)/t35-,42+,43-,46+,48-,64?/m0/s1
|
| Chemical Name |
N-[1-[(1S,3R,4R,6S,7S)-1-[[bis(4-methoxyphenyl)-phenylmethoxy]methyl]-7-[2-cyanoethoxy-[di(propan-2-yl)amino]phosphanyl]oxy-6-methyl-2,5-dioxabicyclo[2.2.1]heptan-3-yl]-5-methyl-2-oxopyrimidin-4-yl]benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1236 mL | 5.6182 mL | 11.2363 mL | |
| 5 mM | 0.2247 mL | 1.1236 mL | 2.2473 mL | |
| 10 mM | 0.1124 mL | 0.5618 mL | 1.1236 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
